| dc.creator |
AFŞAR, Barış |
|
| dc.creator |
Afsar, Rengin Elsurer |
|
| dc.date |
2023-08-01T00:00:00Z |
|
| dc.date.accessioned |
2025-02-25T10:19:27Z |
|
| dc.date.available |
2025-02-25T10:19:27Z |
|
| dc.identifier |
306e791b-87dc-4075-98f7-9fd6156a3d78 |
|
| dc.identifier |
10.1007/s43440-023-00497-x |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/306e791b-87dc-4075-98f7-9fd6156a3d78/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/99243 |
|
| dc.description |
Hypoxia-inducible factor (HIFs) is a new class of drug developed for the management of anemia in chronic kidney disease (CKD) patients. HIFs increase the production of erythropoietin in the kidney and liver, enhance the absorption and utilization of iron, and stimulate the maturation and proliferation of erythroid progenitor cells. Besides, HIFs regulate many physiologic processes by orchestrating the transcription of hundreds of genes. Essential hypertension (HT) is an epidemic worldwide. HIFs play a role in many biological processes involved in the regulation of blood pressure (BP). In the current review, we summarize pre-clinical and clinical studies investigating the relationship between HIFs and BP regulation in patients with CKD, conflicting issues, and discuss future potential strategies. Graphical abstract: [Figure not available: see fulltext.] |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
Hypoxia-inducible factors and essential hypertension: narrative review of experimental and clinical data |
|
| dc.type |
info:eu-repo/semantics/article |
|